Mark Preston retweeted
The B.A.A. mourns the loss of Michael O’Leary, MD, a member of our organization’s family since 1989 and President and Chairman from 2017 through 2023. 💙💛
Double blind RCT of entereg vs placebo in patients undergoing cystectomy within a mature ERAS pathway
@YimKendrick
N=136
~90% open
- No difference in GI recovery, LOS, NG insertion, or readmissions
- 5d median LOS in both groups
#ERAS #AUA2026 @MGBUrology @ErasSociety
Thanks to team at @MassGenBrigham for getting this done. @adamkibel_uro @alexbergermd @MattMossanen @ClintonTim @SLChang1 @qdtrinh
Mark Preston retweeted
Please open and enroll to GAIN. @eugene_pietzak gem-bcg. Bcg exposed. Great trial. We have open and enrolling @NM_Urology
Mark Preston retweeted
The SUO is pleased to introduce FUO: Future Urologic Oncologists, an immersive, in-person educational program designed to introduce senior urology residents to the clinical, collaborative, and leadership dimensions of Urologic Oncology.
Learn more here: bit.ly/4bGE0UI
Mark Preston retweeted
Congratulations to Dr. Vanessa Lukas, Brigham and Women's Hospital Urology resident, on earning a New England Section AUA grant for the proposal, "Chief’s Capstone: Preparing for Life after Residency.”
Well done and well deserved! #AmericanUrologicalAssociation #ResidentDoctors
Mark Preston retweeted
Replying to @UroOnc
This is going to be a great intro to the value of an SUO fellowship + what joining this community of like-minded individuals provides: a career supported in growth, innovation, clinical care + education.
Preference will be given to PGY3s + limited spots available. Apply soon!
Mark Preston retweeted
Congratulations to Matthew Mossanen, MD, MPH, on being selected as a recipient of the 2026 New England American Urological Association Young Urologist of the Year Award! An incredible and well-deserved honor. 👏🎉@MattMossanen @AmerUrological #Urology #AUA #YoungUrologist
Mark Preston retweeted
Interested in catapulting your career in a 1 year fellowship with world-class urologists and an emphasis on innovative imaging, diagnostic, and focal PrCa treatments? Availability July 2026
Happy to share new work from our team now available online @CCR_AACR. We profiled plasma ctDNA dynamics in patients with muscle-invasive bladder cancer (MIBC) treated with bladder-sparing trimodality therapy (TMT)...
doi.org/10.1158/1078-0432.CC…
Mark Preston retweeted
Late Breaking Abstract at #SIU25 in Edinburgh: Tomorrow Seth Lerner will present Immune Response + Preliminary Efficacy Data of AU-011, a First in Class Virus-Like Drug Conjugate #VDC in patients with #NMIBC #BladderCancer #AU011 #Immunotherapy @AuraBiosciences @modulight @SIU_urology @oncodaily @urotoday
Mark Preston retweeted
We are excited to announce @CarvalhoFilipeL as our 2025 Rising Stars in Urology Research Awardee! His groundbreaking work targets immune cells that hinder bladder cancer treatment, paving the way for more effective, personalized therapies.
Read more 👉 bit.ly/47m3Zic
Mark Preston retweeted
Congrats to Dr. Filipe de Carvalho, MD, PhD — recognized as one of the 2025 Rising Stars in Urology Research by the Urology Care Foundation! bit.ly/2025RisingStarsinUrol…
#Urology #ResearchExcellence #BladderCancer #UrologyCareFoundation
@MGHUrology @adamkibel_uro
@AmerUrological
Mark Preston retweeted
Grateful for this year’s speakers presenting at our 10th annual Testicular Cancer Conference presented by @FennecPharma being held at @harvardmed in collaboration with @MassGenBrigham, @DanaFarber, and @Harvard
Visit our website to see the full lineup of incredible speakers at TestesCancer.org
#testicularcancer #UroSoMe #urology #menshealth
Mark Preston retweeted
Looking for an “all things prostate” job, easy call, two teams of residents, loan repayment and great benefits? We are 5 full time urologists looking for a 6th, with 5 APP staff and 4 residents on service at all times. Check us out!
usajobs.gov/job/841886900?ut…
Mark Preston retweeted
📫 Interim results of #Sunrise4 are released @TheLancetOncol
Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC
✅ TAR200+CET: pCR 42%, Major path Response 60%
✅ in cT2 pts baseline: pCR 48%
✅ TAR200 exposure-response association: pCR 50% if TAR200x4 full cycles
Can we cure selected pts with MIBC with intravesical Rx + single agent IO?
Future: is there a way to avoid #radicalcystectomy by consolidating Response with TAR200 in selected pts?
Primary results with full biomarker results are awaited
@Larvol @ASCO @myESMO @OncoAlert @urotoday @Medscape @SanRaffaeleMI @MyUniSR @JNJNews @spsutkaMD @DrFelixGuerrero @evanguelosx @BenjaminPradere
#bladdercancer #clinicalresearch #MedTwitter #neoadjuvant
thelancet.com/journals/lanon…
Mark Preston retweeted
🚨 @AmerUrological is looking for applicants to be on the guidelines panel for hemorrhagic cystitis 🚨
use the link below to apply by the deadline 📥 of july 20th!
auanet.org/guidelines-and-qu…
Mark Preston retweeted
Great job by Ilana E. presenting ctDNA data from our combined @DanaFarber_GU @MGHCancerCenter @BrighamRadOnc cohort of patients with MIBC treated with TMT! Post-treatment ctDNA status is highly prognostic in the TMT setting.
Mark Preston retweeted
Great work @eric_facs ! So important to make sure surgical trials are at the forefront. 👏🏽👏🏽👏🏽
Please help us extend a big #Buckeye congratulations to Dr. Eric Singer (@eric_facs) on his appointment as Co-Chair of the Alliance Surgery Committee! 👏👏👏 @ALLIANCE_org @OSUCCC_James @OSUWexMed @UroOnc @ctleeuro @OhioStateSurg @OhioStateMed #NCI #UroOnc
Mark Preston retweeted
#EAU25 The amazing @spsutkaMD presents the safety results from #SunRise-4 TAR200+ cetrilimab vs cetrilimab
No significant decline in ECOG PS, BMI, albumin, hgb
Overall no delays to RC
Median time to RC 13.5 weeks
30-90 day mortality ~ historical data
Excellent discussion by @paolo_gontero
@UroDocAsh @AndreaNecchi @siadaneshmand @tompowles1 @AStenzl @CarmeMir














































